DURECT Company Description
DURECT wants your medicine to go DURECTly where it's needed. It is developing drug-delivery systems to provide long-term therapy for such conditions as chronic pain, heart disease, cancer, and Alzheimer's. Drug delivery technologies provided by DURECT include SABER, a controlled-release injectable; TRANSDUR, a transdermal patch; ORADUR, a sustained release oral gel-cap; DUROS, an osmotic implant; and DURIN, a biodegradable implant. Its R&D efforts are conducted independently and collaboratively. DURECT sells biodegradable polymers (Lactel) and osmotic pumps (ALZET) to pharmaceutical and medical research firms through direct sales representatives and distributors.
View the Comprehensive Company Description for DURECT
The Company Description provides a historical perspective of DURECT's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of DURECT's evolution in the marketplace.
